Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.
Lisa A KachnicKathryn WinterMohan SuntharalingamDavid IlsonAndré KonskiShane LloydSarah A McAvoyThomas LadOlugbenga Gbenga OlowokurePamela SamsonElizabeth M GoreJoshua E MeyerGregory M M VideticDavid A ClumpAdam RabenOmar KayalehJerry BarkerMichael G HaddockJudith O HopkinsDeborah W BrunerPublished in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2024)
The addition of cetuximab to CRT for the nonoperative management of esophageal cancer did not improve PROs.
Keyphrases
- phase iii
- patient reported outcomes
- open label
- clinical trial
- metastatic colorectal cancer
- minimally invasive
- phase ii
- locally advanced
- wild type
- double blind
- coronary artery bypass
- palliative care
- placebo controlled
- heart failure
- randomized controlled trial
- newly diagnosed
- rectal cancer
- percutaneous coronary intervention
- acute coronary syndrome
- left ventricular
- coronary artery disease
- chemotherapy induced